-
Views
-
Cite
Cite
Nina Liu, Jason E. Cummings, Kathleen England, Richard A. Slayden, Peter J. Tonge, Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei, Journal of Antimicrobial Chemotherapy, Volume 66, Issue 3, March 2011, Pages 564–573, https://doi.org/10.1093/jac/dkq509
- Share Icon Share
Abstract
As an initial step in developing novel antibacterials against Burkholderia pseudomallei, we have characterized the FabI enoyl-ACP reductase homologues in the type II fatty acid biosynthesis pathway from this organism and performed an initial enzyme inhibition study.
A BLAST analysis identified two FabI enoyl-ACP reductase homologues, bpmFabI-1 and bpmFabI-2, in the B. pseudomallei genome, which were cloned, overexpressed in Escherichia coli and purified. Steady-state kinetics was used to determine the reaction mechanism and the sensitivity of bpmFabI-1 to four diphenyl ether FabI inhibitors. The antibacterial activity of the inhibitors was assessed using a wild-type strain of Burkholderia thailandensis (E264) and an efflux pump mutant (Bt38).
Consistent with its annotation as an enoyl-ACP reductase, bpmFabI-1 catalysed the NADH-dependent reduction of 2-trans-dodecenoyl-CoA via a sequential Bi Bi mechanism. In contrast, bpmFabI-2 was inactive with all substrates tested and only bpmfabI-1 was transcriptionally active under the growth conditions employed. The sensitivity of bpmFabI-1 to four diphenyl ethers was evaluated and in each case the compounds were slow-onset inhibitors with Ki values of 0.5–2 nM. In addition, triclosan and PT01 had MIC values of 30 and 70 mg/L for B. pseudomallei as well as a wild-type strain of B. thailandensis (E264), but MIC values of <1 mg/L for the efflux pump mutant Bt38. A reduction in MIC values was also observed for the pump mutant strain with the other diphenyl ethers.
Provided that efflux can be circumvented, bpmFabI-1 is a suitable target for drug discovery.
- steady state
- burkholderia
- burkholderia pseudomallei
- coenzyme a
- ethers
- genome
- mechlorethamine
- nicotinamide adenine dinucleotide (nad)
- new mexico
- oxidoreductase
- triclosan
- enzymes
- kinetics
- anti-bacterial agents
- escherichia coli
- fatty acid biosynthesis
- drug discovery
- basic local alignment search tool
- symptom onset